Viatris Inc (VTRS)
Industry Drug Manufacturers - Specialty & Generic
This stock can be held in an Investment ISA and an Investment Account
Sell
$11.20
Buy
$11.26
$0.06 (+0.54%)
Prices updated at 25 Jan 2025, 00:25 EST
| Prices minimum 15 mins delay
Prices in USD
Mylan NV is a generic pharmaceutical manufacturer which develops, licenses, manufactures, markets and distributes generic, over-the-counter (OTC) products in a variety of dosage forms and therapeutic categories.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
|---|---|
| 2023 | 41.74 |
| 2022 | 39.95 |
| 2021 | 31.17 |
| 2020 | 31.78 |
| 2019 | 33.89 |
| 2018 | 35.00 |
| 2017 | 40.17 |
| 2016 | 42.40 |
Valuation data table
Year | Price / Sales |
|---|---|
| 2025 | 0.89 |
| 2024 | 0.99 |
| 2023 | 0.85 |
| 2022 | 0.81 |
| 2021 | 0.88 |
| 2020 | 0.84 |
| 2019 | 0.91 |
| 2018 | 1.23 |
| 2017 | 1.90 |
| 2016 | 1.90 |
| 2015 | 2.82 |
Price/Forward earnings (YTD)
4.15
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
|---|---|
| 2023 | 0.11 |
| 2022 | 3.96 |
| 2021 | -2.18 |
| 2020 | -1.44 |
| 2019 | 0.05 |
| 2018 | 1.03 |
| 2017 | 1.97 |
| 2016 | 1.68 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2023 | 2.33 |
| 2022 | 2.37 |
| 2021 | 2.68 |
| 2020 | 2.68 |
| 2019 | 2.63 |
| 2018 | 2.69 |
| 2017 | 2.69 |
| 2016 | 3.12 |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
